Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027672 | 0.96 | F10 (0.61) | F10KCNH2JAK2JAK1TYK2 | |
| SCHEMBL12955997 | 0.96 | F10 (0.61) | F10KCNH2JAK2JAK1TYK2 | |
| SCHEMBL8262273 | 0.96 | F10 (0.61) | F10KCNH2JAK2JAK1TYK2 | |
| SCHEMBL1029183 | 0.87 | F10 (0.57) | F10 | |
| SCHEMBL1029306 | 0.83 | F10 (0.52) | F10KCNH2JAK2JAK1TYK2 | |
| SCHEMBL8261113 | 0.83 | F10 (0.52) | F10KCNH2JAK2JAK1TYK2 | |
| SCHEMBL4709195 | 0.82 | F10 (0.56) | F10JAK2JAK1TYK2JAK3 | |
| SCHEMBL1026247 | 0.80 | F10 (0.81) | F10KCNH2 | |
| SCHEMBL1029728 | 0.80 | F10 (0.81) | F10KCNH2 | |
| SCHEMBL8241630 | 0.80 | F10 (0.56) | F10KCNH2JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | claimed |
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-7501413-B2 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501413-B2 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | F2, F12, TFPI | F10 8/4885KCNH2 1702/4885JAK2 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.